Tufts CSDD Report on New Patient Recruitment/Retention Approaches
New approaches include using Big Data to identify and understand patient populations, engaging the “voice of the patient” in trial design, and using new technologies and social media to reach, attract, and keep patients.
According to R&D leaders participating in a roundtable hosted by the Tufts Center for the Study of Drug Development, drug developers are innovating clinical study volunteer recruitment and retention to significantly improve clinical trial performance and efficiency. Some new approaches include using Big Data to identify and understand patient populations, engaging the “voice of the patient” in trial design, and using new technologies and social media to reach, attract, and keep patients.
Other points made at the Tufts CSDD Executive Forum, summarized in the January Tufts CSDD R&D Management Report, released today, include the following:
- Patient-centric study teams are using real-time data to understand and adjust the patient recruitment process as it unfolds.
- Improve outreach to referring physicians, a primary conduit to clinical trial patients, as 82% of physicians say they’d be more willing to refer patients if they developed a working relationship with a clinical trial investigator.
- Social media, which already supports communication within patient communities, will grow as a recruitment tool by providing new pathways between sites and specific population groups.
- Comprehensive electronic medical records (EMRs) and health files will play a major role in patient recruitment within five years.
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
